SMAD1 and pulmonary arterial hypertension: In the two decades since BMPRII deficiency was first implicated in the development of PAH, many approaches to promote SMAD1/5/8 pathway signaling in the pulmonary vasculature have been evaluated in PAH models and, in a few cases, clinically (Table 1).